Tiotropium: What came after the UPLIFT study

Pierachille Santus, Fabiano Di Marco, Dejan Radovanovic, Stefano Centanni

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) is characterized by a progressive bronchial obstruction, and bronchodilators represent the maintenance therapeutic choice. Tiotropium is an anticholinergic drug that is proved to be safe, efficient and simple to handle; Respimat® technology was recently introduced as a new device for tiotropium administration. Areas covered: This paper reviews clinical trials and meta-analyses, with tiotropium efficacy as a primary end point, found in MedLine, the Cochrane trials database and Embase. Only the literature published after the UPLIFT study has been considered. Expert opinion: Data published after the UPLIFT study confirms the efficacy of tiotropium as maintenance COPD therapy and its capacity to reduce airflow obstruction, as well as lung hyperinflation. Nevertheless, there is a certain inhomogeneity in the definition and evaluation of COPD exacerbations, in lung functional parameters and quality-of-life assessment, and there has not always been a proper comparison between tiotropium and other long-acting bronchodilators. Respimat is comparable in efficacy to the HandiHaler®, using bioequivalent doses of tiotropium.

Original languageEnglish
Pages (from-to)613-618
Number of pages6
JournalExpert Opinion on Pharmacotherapy
Volume13
Issue number4
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Chronic Obstructive Pulmonary Disease
Bronchodilator Agents
Maintenance
Lung
Expert Testimony
Cholinergic Antagonists
Disease Progression
Meta-Analysis
Tiotropium Bromide
Quality of Life
Clinical Trials
Databases
Technology
Equipment and Supplies
Therapeutics
Pharmaceutical Preparations

Keywords

  • Anticholinergic
  • COPD
  • Outcome
  • Respimat
  • Tiotropium

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Santus, P., Di Marco, F., Radovanovic, D., & Centanni, S. (2012). Tiotropium: What came after the UPLIFT study. Expert Opinion on Pharmacotherapy, 13(4), 613-618. https://doi.org/10.1517/14656566.2012.656592

Tiotropium : What came after the UPLIFT study. / Santus, Pierachille; Di Marco, Fabiano; Radovanovic, Dejan; Centanni, Stefano.

In: Expert Opinion on Pharmacotherapy, Vol. 13, No. 4, 03.2012, p. 613-618.

Research output: Contribution to journalArticle

Santus, P, Di Marco, F, Radovanovic, D & Centanni, S 2012, 'Tiotropium: What came after the UPLIFT study', Expert Opinion on Pharmacotherapy, vol. 13, no. 4, pp. 613-618. https://doi.org/10.1517/14656566.2012.656592
Santus, Pierachille ; Di Marco, Fabiano ; Radovanovic, Dejan ; Centanni, Stefano. / Tiotropium : What came after the UPLIFT study. In: Expert Opinion on Pharmacotherapy. 2012 ; Vol. 13, No. 4. pp. 613-618.
@article{0d3cd29a88fe40148d3daeea4b5fd646,
title = "Tiotropium: What came after the UPLIFT study",
abstract = "Introduction: Chronic obstructive pulmonary disease (COPD) is characterized by a progressive bronchial obstruction, and bronchodilators represent the maintenance therapeutic choice. Tiotropium is an anticholinergic drug that is proved to be safe, efficient and simple to handle; Respimat{\circledR} technology was recently introduced as a new device for tiotropium administration. Areas covered: This paper reviews clinical trials and meta-analyses, with tiotropium efficacy as a primary end point, found in MedLine, the Cochrane trials database and Embase. Only the literature published after the UPLIFT study has been considered. Expert opinion: Data published after the UPLIFT study confirms the efficacy of tiotropium as maintenance COPD therapy and its capacity to reduce airflow obstruction, as well as lung hyperinflation. Nevertheless, there is a certain inhomogeneity in the definition and evaluation of COPD exacerbations, in lung functional parameters and quality-of-life assessment, and there has not always been a proper comparison between tiotropium and other long-acting bronchodilators. Respimat is comparable in efficacy to the HandiHaler{\circledR}, using bioequivalent doses of tiotropium.",
keywords = "Anticholinergic, COPD, Outcome, Respimat, Tiotropium",
author = "Pierachille Santus and {Di Marco}, Fabiano and Dejan Radovanovic and Stefano Centanni",
year = "2012",
month = "3",
doi = "10.1517/14656566.2012.656592",
language = "English",
volume = "13",
pages = "613--618",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Tiotropium

T2 - What came after the UPLIFT study

AU - Santus, Pierachille

AU - Di Marco, Fabiano

AU - Radovanovic, Dejan

AU - Centanni, Stefano

PY - 2012/3

Y1 - 2012/3

N2 - Introduction: Chronic obstructive pulmonary disease (COPD) is characterized by a progressive bronchial obstruction, and bronchodilators represent the maintenance therapeutic choice. Tiotropium is an anticholinergic drug that is proved to be safe, efficient and simple to handle; Respimat® technology was recently introduced as a new device for tiotropium administration. Areas covered: This paper reviews clinical trials and meta-analyses, with tiotropium efficacy as a primary end point, found in MedLine, the Cochrane trials database and Embase. Only the literature published after the UPLIFT study has been considered. Expert opinion: Data published after the UPLIFT study confirms the efficacy of tiotropium as maintenance COPD therapy and its capacity to reduce airflow obstruction, as well as lung hyperinflation. Nevertheless, there is a certain inhomogeneity in the definition and evaluation of COPD exacerbations, in lung functional parameters and quality-of-life assessment, and there has not always been a proper comparison between tiotropium and other long-acting bronchodilators. Respimat is comparable in efficacy to the HandiHaler®, using bioequivalent doses of tiotropium.

AB - Introduction: Chronic obstructive pulmonary disease (COPD) is characterized by a progressive bronchial obstruction, and bronchodilators represent the maintenance therapeutic choice. Tiotropium is an anticholinergic drug that is proved to be safe, efficient and simple to handle; Respimat® technology was recently introduced as a new device for tiotropium administration. Areas covered: This paper reviews clinical trials and meta-analyses, with tiotropium efficacy as a primary end point, found in MedLine, the Cochrane trials database and Embase. Only the literature published after the UPLIFT study has been considered. Expert opinion: Data published after the UPLIFT study confirms the efficacy of tiotropium as maintenance COPD therapy and its capacity to reduce airflow obstruction, as well as lung hyperinflation. Nevertheless, there is a certain inhomogeneity in the definition and evaluation of COPD exacerbations, in lung functional parameters and quality-of-life assessment, and there has not always been a proper comparison between tiotropium and other long-acting bronchodilators. Respimat is comparable in efficacy to the HandiHaler®, using bioequivalent doses of tiotropium.

KW - Anticholinergic

KW - COPD

KW - Outcome

KW - Respimat

KW - Tiotropium

UR - http://www.scopus.com/inward/record.url?scp=84857241069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857241069&partnerID=8YFLogxK

U2 - 10.1517/14656566.2012.656592

DO - 10.1517/14656566.2012.656592

M3 - Article

C2 - 22283503

AN - SCOPUS:84857241069

VL - 13

SP - 613

EP - 618

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 4

ER -